Statin therapy and related risk of new-onset type 2 diabetes mellitus

European Journal of Internal Medicine

Volumn 25, Issue 5, 2014, Pages 401-406

  Ruscica, Massimiliano ^a,b   MacChi, Chiara ^a,b   Morlotti, Beatrice ^b   Sirtori, Cesare R ^a,b   Magni, Paolo ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cardiovascular risk; New onset diabetes risk; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN;

CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; SECONDARY PREVENTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRAVASTATIN; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION;

EID: 84901631304     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.03.003     Document Type: Review

References (53)

1. F.C. Taylor, M. Huffman, and S. Ebrahim Statin therapy for primary prevention of cardiovascular disease JAMA 310 2013 2451 2452
2. D. Preiss, and N. Sattar Pharmacotherapy: statins and new-onset diabetes - the important questions Nat Rev Cardiol 9 2012 190 192
3. S.A. Metz, M.E. Rabaglia, J.B. Stock, and A. Kowluru Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins Biochem J 295 1993 31 40
4. M. Ohrvall, H. Lithell, J. Johansson, and B. Vessby A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia Metabolism 44 1995 212 217
5. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, and A.J. de Craen et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
6. S. Mora, R.J. Glynn, J. Hsia, J.G. MacFadyen, J. Genest, and P.M. Ridker Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials Circulation 121 2010 1069 1077
7. J.C. Chan, V. Malik, W. Jia, T. Kadowaki, C.S. Yajnik, and K.H. Yoon et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology JAMA 301 2009 2129 2140
8. P.M. Ridker, J. Genest, S.M. Boekholdt, P. Libby, A.M. Gotto, and B.G. Nordestgaard et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2012 333 339
9. Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, and O. Wiklund et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
10. Z. Reiner Combined therapy in the treatment of dyslipidemia Fundam Clin Pharmacol 24 2010 19 28
11. A. Poli, and A. Corsini Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials Eur J Intern Med 21 2010 372 373
12. N. Singh, J. Tamariz, G. Chamorro, and J.L. Medina-Franco Inhibitors of HMG-CoA reductase: current and future prospects Mini Rev Med Chem 9 2009 1272 1283
13. A. Corsini, T.A. Jacobson, and C.M. Ballantyne Fluvastatin: clinical and safety profile Drugs 64 2004 1305 1323
14. Sugerman DT, Livingston EH,Lynm C. JAMA patient page. Statins. JAMA; 309:1419
15. D.J. Freeman, J. Norrie, N. Sattar, R.D. Neely, S.M. Cobbe, and I. Ford et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 2001 357 362
16. (EMA) EMA. HMG-CoA reductase inhibitors - Risk of new onset diabetes 22 March 2012 [cited; Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Report/2012/01/WC500120115.pdf 2012
17. (FDA) TUSFaDA FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs [cited; Available from: http://www.fda.gov/drugs/drugsafety/ucm293101.htm 2012
18. S.G. Wannamethee, A.G. Shaper, P.H. Whincup, L. Lennon, and N. Sattar Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors Arch Intern Med 171 2011 404 410
19. J.M. Chehade, M. Gladysz, and A.D. Mooradian Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management Drugs 73 2013 327 339
20. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
21. E.J. Mills, P. Wu, G. Chong, I. Ghement, S. Singh, and E.A. Akl et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials QJM 104 2011 109 124
22. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, and D.D. Waters et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
23. S.N. Rajpathak, D.J. Kumbhani, J. Crandall, N. Barzilai, M. Alderman, and P.M. Ridker Statin therapy and risk of developing type 2 diabetes: a meta-analysis Diabetes Care 32 2009 1924 1929
24. E.P. Navarese, A. Buffon, F. Andreotti, M. Kozinski, N. Welton, and T. Fabiszak et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus Am J Cardiol 111 2013 1123 1130
25. A.L. Culver, I.S. Ockene, R. Balasubramanian, B.C. Olendzki, D.M. Sepavich, and J. Wactawski-Wende et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative Arch Intern Med 172 2012 144 152
26. N.L. Zaharan, D. Williams, and K. Bennett Statins and risk of treated incident diabetes in a primary care population Br J Clin Pharmacol 75 2012 1118 1124
27. T. Ma, M.H. Chang, L. Tien, Y.S. Liou, and G.P. Jong The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study Drugs Aging 29 2012 45 51
28. T. Ma, L. Tien, C.L. Fang, Y.S. Liou, and G.P. Jong Statins and new-onset diabetes: a retrospective longitudinal cohort study Clin Ther 34 2012 1977 1983
29. A.A. Carter, T. Gomes, X. Camacho, D.N. Juurlink, B.R. Shah, and M.M. Mamdani Risk of incident diabetes among patients treated with statins: population based study BMJ 346 2013 f2610
30. C.W. Chen, T.C. Chen, K.Y. Huang, P. Chou, P.F. Chen, and C.C. Lee Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an Asian country PLoS One 8 2013 e71817
31. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, and S.M. Cobbe et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
32. A. Keech, D. Colquhoun, J. Best, A. Kirby, R.J. Simes, and D. Hunt et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial Diabetes Care 26 2003 2713 2721
33. M.S. Sabatine, S.D. Wiviott, D.A. Morrow, and C.H. McCabe High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy Cannon CP,834 HdaawwgcAP-ITsCS Circulation 110 2004 [SIII]
34. D.D. Waters, J.E. Ho, D.A. DeMicco, A. Breazna, B.J. Arsenault, and C.C. Wun et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
35. N. Hounslow, P. Robillard, M. Suzuki, P. Betting, P. Giral, and M.J. Chapman Pitavastatin is without effect on glycaemic parameters in metabolic syndrome (CAPITAIN Study) 2012 Abstract presented at World Diabetes Congress
36. T. Teramoto, H. Shimano, K. Yokote, and M. Urashima New evidence on pitavastatin: efficacy and safety in clinical studies Expert Opin Pharmacother 11 2010 817 828
37. H. Ginsberg Statins in cardiometabolic disease: what makes pitavastatin different? Cardiovasc Diabetol 12 2013 S1
38. N. Sattar, and M.R. Taskinen Statins are diabetogenic - myth or reality? Atheroscler Suppl 13 2012 1 10
39. D.D. Waters, J.E. Ho, S.M. Boekholdt, D.A. DeMicco, J.J. Kastelein, and M. Messig et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes J Am Coll Cardiol 61 2013 148 152
40. L. Shen, B.R. Shah, E.M. Reyes, L. Thomas, D. Wojdyla, and P. Diem et al. Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study BMJ 347 2013 f6745
41. J. Puurunen, T. Piltonen, K. Puukka, A. Ruokonen, M.J. Savolainen, and R. Bloigu et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study J Clin Endocrinol Metab 98 2013 4798 4807
42. K.D. Ballard, E.E. Quann, B.R. Kupchak, B.M. Volk, D.M. Kawiecki, and M.L. Fernandez et al. Dietary carbohydrate restriction improves insulin sensitivity, blood pressure, microvascular function, and cellular adhesion markers in individuals taking statins Nutr Res 33 2013 905 912
43. WHO Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus 2011 WHO Publication [cited; Available from: http://www.who.int/ diabetes/publications/report-hba1c-2011.pdf
44. Association. AD. Diagnosis and classification of diabetes mellitus Diabetes Care 35 2012 S64 S71
45. M.J. Gillett International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: diabetes care 2009; 32(7): 1327-1334 Clin Biochem Rev 30 2009 197 200
46. E.K. Reindl, B.M. Wright, and K.A. Wargo Alternate-day statin therapy for the treatment of hyperlipidemia Ann Pharmacother 44 2010 1459 1470
47. J.J. Li, P. Yang, J. Liu, Y.J. Jia, Z.C. Li, and Y.L. Guo et al. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers Clin Chim Acta 413 2012 139 142
48. F.I. Marcus, A.J. Baumgarten, W.L. Fritz, and P.E. Nolan Jr. Alternate-day dosing with statins Am J Med 126 2013 99 104
49. A.S. Wierzbicki, A. Viljoen, T.C. Hardman, and D.P. Mikhailidis New therapies to reduce low-density lipoprotein cholesterol Curr Opin Cardiol 28 2013 452 457
50. M. Florentin, E.N. Liberopoulos, C.V. Rizos, A.A. Kei, G. Liamis, and M.S. Kostapanos et al. Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose Metab Syndr Relat Disord 11 2013 152 156
51. G. Derosa, P. Maffioli, and A.F. Cicero Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials Expert Opin Biol Ther 12 2012 1113 1124
52. M. Ruscica, M. Gomaraschi, G. Mombelli, C. Macchi, R. Bosisio, and F. Pazzucconi et al. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with armolipid plus J Clin Lipidol 8 2014 61 68
53. K. Axsom, J.S. Berger, and A.Z. Schwartzbard Statins and diabetes: the good, the bad, and the unknown Curr Atheroscler Rep 15 2013 299